TRVI
Trevi Therapeutics Inc
NASDAQ: TRVI · HEALTHCARE · BIOTECHNOLOGY
$13.82
-0.14% today
Updated 2026-04-29
Market cap
$1.96B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.32
Dividend yield
—
52W range
$5 – $16
Volume
1.5M
Trevi Therapeutics Inc (TRVI) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-11.19M | $-7.97M | $-18.29M | $-23.09M | $-29.00M | $-28.95M | $-28.18M | $-31.71M | $-38.26M | $-42.09M |
| Capital expenditures | $13000.00 | $13000.00 | $158000.00 | $9000.00 | $32000.00 | $159000.00 | $159000.00 | $137000.00 | $35000.00 | $12000.00 |
| Depreciation | $4000.00 | $4000.00 | $23000.00 | $39000.00 | $47000.00 | $50000.00 | $43000.00 | $123000.00 | $147000.00 | — |
| Stock-based comp | $142.00 | $205000.00 | $496000.00 | $1.13M | $2.42M | $2.54M | $2.33M | $2.25M | $3.59M | $5.18M |
| Free cash flow | $-11.21M | $-7.99M | $-18.45M | $-23.10M | $-29.03M | $-29.11M | $-28.33M | $-31.85M | $-38.29M | $-42.10M |
| Investing cash flow | $-13000.00 | $-13000.00 | $-158000.00 | $-9000.00 | $-32000.00 | $-107.37M | $-107.37M | $59.43M | $-21.53M | — |
| Financing cash flow | $8.60M | $21.72M | $3629.00 | $73.21M | $16.72M | $20.77M | $111.31M | $-7.91M | $61.48M | — |
| Dividends paid | $0.00 | $0.00 | $0.00 | $2.24M | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $-12.31M | — | $-24.24M | — | — | — |